NVP-HDM201 (147), also known as siremadlin, is an imidazolpyrrolidone analog developed by Novartis that has demonstrated highly favorable in vivo properties as an orally effective and selective MDM2-p53 inhibitor and recently entered phase I clinical trials in cancer patients. This evidence concerns the gene TP53 and cancer.